Recs

1

This Blockbuster Drug Just Got Better

By David Williamson | More Articles
January 31, 2012 | Comments (0)

The following video is part of our "Motley Fool Conversations" series, in which health-care editor and analyst David Williamson and consumer goods editor and analyst Austin Smith discuss topics across the investing world.

The roller coaster ride for best-in-class multiple sclerosis drug Tysabri looks like it is coming to a satisfying conclusion for investors, and for about half the population struggling with MS. David and Austin discuss how a new test has changed the fortune of this drug, and its makers, in this video.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Austin Smith owns shares of Pfizer. David Williamson owns shares of Pfizer. The Motley Fool owns shares of Teva Pharmaceutical Industries. Motley Fool newsletter services recommend Quest Diagnostics, Elan, Pfizer and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 1769548, ~/Articles/ArticleHandler.aspx, 5/27/2012 11:35:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:00 PM
BIIB $131.56 Down -0.09 -0.07%
Biogen Idec CAPS Rating: ***
TEVA $38.61 Down -0.08 -0.21%
Teva Pharmaceutica… CAPS Rating: *****
PFE $22.13 Down -0.01 -0.05%
Pfizer, Inc. CAPS Rating: ****
DGX $58.00 Up +0.59 +1.03%
Quest Diagnostics,… CAPS Rating: ****

Advertisement